Given this multifunctional involvement, NG2 has been proposed as a promising target for chimeric antigen receptor (CAR)-T-cell therapy in several malignancies, marking a significant advancement beyond the early efforts to develop immunotherapeutic approaches for TNBC and basal-like cancers [59]. Here, CSPG4 is linked to cancer.